NAD Benefits: Clinical Evidence & Biomarker Insights

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme critical to cellular energy production and DNA repair. Research indicates NAD+ levels naturally decline with age—approximately 50% by age 60—potentially affecting mitochondrial function and metabolic efficiency in ways that may influence overall wellness strategies.

Understanding NAD+ benefits requires more than marketing claims; it demands biomarker context and individual metabolic assessment. PlexusDx supports precision-wellness conversations by helping patients and providers evaluate whether NAD+ optimization aligns with their specific metabolic profile and health goals.

How NAD+ Functions in Cellular Health

NAD+ participates in two primary roles: energy metabolism through mitochondrial respiration and signaling pathways that regulate cellular stress responses. As NAD+ declines, cells may show reduced efficiency in ATP production and diminished capacity for DNA damage repair, processes linked to aging and metabolic dysfunction.

Clinical studies have explored NAD+ restoration through precursors like NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide). Evidence suggests these may improve mitochondrial function and exercise capacity in some populations, though individual variation remains significant and often correlates with baseline NAD+ status and age.

NAD+ Research Evidence and Clinical Context

Research on NAD+ benefits spans multiple domains—cardiovascular health, metabolic flexibility, cognitive function, and aging biomarkers. Below is a framework for understanding the current evidence landscape and how baseline factors influence interpretation.

Research Domain	Evidence Level	Key Biomarker Context
Mitochondrial function and ATP production	Solid preclinical; human data limited	Age 50+, baseline NAD+ status, exercise capacity
Metabolic flexibility and glucose handling	Emerging human studies	Insulin sensitivity, fasting glucose, metabolic rate
Cardiovascular and vascular function	Moderate in animal models; limited RCTs in humans	Endothelial dysfunction, hypertension, arterial stiffness
Cognitive and neurological aging	Promising preclinical; human RCTs ongoing	Cognitive decline rate, neuroinflammation markers, age
NAD+-dependent sirtuin activation (longevity pathways)	Mechanistic studies; human outcome data limited	Circulating NAD+ ratio, age, mitochondrial burden

Individual Variation in NAD+ Response

Not all patients benefit equally from NAD+ supplementation. Response variation stems from baseline NAD+ levels, age, mitochondrial health, genetic predispositions in energy metabolism pathways, and lifestyle factors including exercise and sleep quality. Biomarker assessment before starting NAD+ can inform realistic expectations.

Genetic factors influencing NAD+ metabolism and sirtuin signaling (e.g., SIRT1, SIRT3, NAMPT gene variants) may affect how efficiently patients restore NAD+ and activate downstream repair pathways. A provider-guided biomarker and genetic evaluation helps contextualize whether NAD+ fits within a broader precision-wellness approach.

Safety, Eligibility, and Provider-Guided Implementation

NAD+ supplementation is generally well-tolerated in healthy adults. Common considerations include mild nausea or flushing with certain precursors (NR, NMN), potential effects on nicotinamide metabolism in those with liver or kidney disease, and interactions with medications affecting NAD+-dependent pathways. Baseline health assessment is essential.

NAD+ optimization fits within a broader metabolic wellness strategy, not as a standalone intervention. Providers should evaluate baseline energy, sleep, exercise capacity, metabolic labs, and age before recommending NAD+ support. Combining assessment with lifestyle interventions (exercise, sleep, nutrition) typically yields more meaningful outcomes than supplementation alone.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test may help provide biomarker and genetic context relevant to NAD+ metabolism and cellular repair pathways, including predispositions in mitochondrial efficiency genes. This information should be interpreted alongside clinical labs and a qualified provider's assessment—genetic predisposition does not predict exact NAD+ response or clinical benefit.

The genetic test reveals predispositions in peptide and metabolic pathways (FTO, MC4R, GIPR, and GLP1R variants) that contextualize metabolic flexibility and energy production efficiency. Patients with certain genetic profiles may show different baseline NAD+ status or mitochondrial capacity, informing whether NAD+ support aligns with their metabolic strategy.

Understanding your genetic context and baseline biomarkers can support a more informed conversation with your healthcare provider about whether NAD+ optimization fits your personalized wellness plan. PlexusDx helps patients move beyond generic recommendations toward precision-guided decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the clinical evidence for NAD+ benefits in aging?

Research shows NAD+ levels decline ~50% by age 60, and preclinical studies suggest restoration may support mitochondrial function and cellular repair. Human clinical trials remain limited; outcomes vary based on baseline NAD+ status, age, and individual metabolic factors. Consult a provider about realistic expectations.

How does baseline NAD+ status affect supplementation response?

Patients with lower baseline NAD+ (common in older adults or those with metabolic stress) may show more noticeable improvements than those with adequate baseline levels. Biomarker testing can help assess whether NAD+ restoration is a priority for your specific health profile.

Can genetic factors influence NAD+ metabolism and response?

Yes. Variants in genes affecting mitochondrial function, sirtuin signaling, and NAD+ synthesis (SIRT1, SIRT3, NAMPT) may influence baseline capacity and response to supplementation. PlexusDx Precision Peptide Genetic Test may help provide this context for provider discussions.

Are there side effects or safety concerns with NAD+ supplementation?

NAD+ precursors (NR, NMN) are generally well-tolerated; mild nausea or flushing may occur. Those with liver, kidney disease, or taking medications affecting NAD+ pathways should discuss use with a provider. Baseline health assessment ensures safety and identifies contraindications.

How does NAD+ relate to metabolic health and GLP-1 pathway function?

Both NAD+ and GLP-1 signaling influence mitochondrial efficiency and glucose metabolism. Some patients optimizing metabolic health address both pathways. PlexusDx can contextualize your genetic predispositions in these pathways to support a comprehensive provider conversation about which interventions align with your goals.

NAD Benefits: Biomarker Context and Provider-Guided Evaluation

NAD+ is a coenzyme involved in cellular energy and repair processes. Clinical research suggests potential benefits in mitochondrial function and metabolic health, though individual response varies significantly based on age, baseline biomarkers, and genetic factors.